CMO Dr. Andrew Hertler Reacts to the FDA's Recent ODAC Meeting

CMO Dr. Andrew Hertler on the Recent FDA ODAC Meeting

The FDA's Oncologic Drugs Advisory Committee (ODAC) met for the first time in a decade to review the merits of approved cancer drugs and specifically, the status of six indications that were granted accelerated approval. New Century Health CMO Dr. Andrew Hertler recently shared his reactions to ODAC's decisions and his reflections on the clinical oversight and scientific rigor that defines New Century Health's pathway development.
 

 

Previous Article
Hitting the Brakes on Fast-Tracked Drugs
Hitting the Brakes on Fast-Tracked Drugs

The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncolog...

Next Article
Traditional UM Programs Can't Move the Needle in Cardiology Care. Here's What Does.
Traditional UM Programs Can't Move the Needle in Cardiology Care. Here's What Does.

Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular managemen...